LAIYANG, China, Aug. 25 /PRNewswire-Asia-FirstCall/ -- Jiangbo
Pharmaceuticals, Inc. (Nasdaq: JGBO) (the "Company" or "Jiangbo"), today
announced that Mr. Wubo Cao, the Company's Chairman, will ring the Opening
Bell at the NASDAQ MarketSite in New York City on Friday, August 27, 2010 at
9:30 a.m. ET to celebrate the Company's listing on the NASDAQ Stock Market.
Jiangbo began trading on the NASDAQ Capital Market on June 8, 2010, under the ticker symbol "JGBO".
"Our Opening Bell ringing ceremony at the NASDAQ MarketSite marks the culmination of our efforts to list our shares on a world-class stock exchange," said Mr. Cao. "We appreciate the dedication of our shareholders, employees, board of directors, and advisors who have enabled us to reach this critical milestone as a public company."
A live webcast of the NASDAQ Opening Bell (starting from 9:20 a.m. ET) will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
Advertisement
Jiangbo began trading on the NASDAQ Capital Market on June 8, 2010, under the ticker symbol "JGBO".
"Our Opening Bell ringing ceremony at the NASDAQ MarketSite marks the culmination of our efforts to list our shares on a world-class stock exchange," said Mr. Cao. "We appreciate the dedication of our shareholders, employees, board of directors, and advisors who have enabled us to reach this critical milestone as a public company."
Advertisement
A live webcast of the NASDAQ Opening Bell (starting from 9:20 a.m. ET) will be available at: http://www.nasdaq.com/about/marketsitetowervideo.asx .
About Jiangbo Pharmaceuticals, Inc.
Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (http://www.jiangbopharma.com ).
Safe Harbor Statement
Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to execute its strategic plan. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
For more information, please contact:
Jiangbo Pharmaceuticals, Inc.
Ms. Elsa Sung, CFO
Phone: +1-954-903-9378 x2
Email: [email protected]
Web: http:// www.jiangbopharma.com
CCG Investor Relations
Mr. Crocker Coulson, President
Phone: +1-646-213-1915
Email: [email protected]
Web: http://www.ccgirasia.com
SOURCE Jiangbo Pharmaceuticals, Inc.